Predicted protein targets (top 2)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | BCL2 | P10415 | 20/20 | 0.65 |
| ▸ | BCL2L1 | Q07817 | 9/20 | 0.65 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL30314134 | 0.94 | BCL2 (0.68) | BCL2BCL2L1 | |
| SCHEMBL29796374 | 0.92 | BCL2 (0.71) | BCL2BCL2L1 | |
| SCHEMBL29796468 | 0.91 | BCL2 (0.61) | BCL2BCL2L1 | |
| SCHEMBL1872740 | 0.91 | BCL2 (0.61) | BCL2BCL2L1 | |
| SCHEMBL30313984 | 0.91 | BCL2 (0.61) | BCL2BCL2L1 | |
| SCHEMBL29657415 | 0.91 | BCL2 (0.62) | BCL2BCL2L1 | |
| SCHEMBL2727181 | 0.91 | BCL2 (0.57) | BCL2BCL2L1 | |
| SCHEMBL29657396 | 0.91 | BCL2 (0.57) | BCL2BCL2L1 | |
| SCHEMBL30313834 | 0.90 | BCL2 (0.66) | BCL2BCL2L1 | |
| SCHEMBL30314240 | 0.90 | BCL2 (0.61) | BCL2BCL2L1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 5 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-2435432-B3 | APOPTOSIS-INDUCING AGENTS FOR THE TREATMENT OF CANCER AND IMMUNE AND AUTOIMMUNE DISEASES | ABBVIE IRELAND UNLIMITED CO (BM) | 2023-10-25 | — | — | EP | disclosed |
| CN-116635062-A | Combination therapy using Chimeric Antigen Receptor (CAR) expressing cells | 诺华股份有限公司 | 2023-08-22 | — | — | CN | disclosed |
| US-20230143532-A1 | APOPTOSIS INDUCING AGENTS FOR THE TREATMENT OF CANCER AND IMMUNE AND AUTOIMMUNE DISEASES | ABBVIE INC. (US) | 2023-05-11 | — | — | US | disclosed |
| CN-114786679-A | Combination therapy with Vernetork and TIM-3 inhibitors | 诺华股份有限公司 | 2022-07-22 | — | — | CN | disclosed |
| CN-114786680-A | TIM-3 inhibitors and uses thereof | 诺华股份有限公司 | 2022-07-22 | — | — | CN | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20230143532-A1 | APOPTOSIS INDUCING AGENTS FOR THE TREATMENT OF CANCER AND IMMUNE AND AUTOIMMUNE DISEASES | BCL2, BAX, BCL3 | BCL2 1/4885BCL2L1 4/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.